DC-S239

• Description :

  DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity[1].

• UNSPSC :

  12352005

• Target :

  Histone Methyltransferase

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dc-s239.html

• Purity :

  99.73

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(OCC)C1=C(SC(C(NC2=CC=CC([N+]([O-])=O)=C2)=O)=C1C)N

• Molecular Formula :

  C15H15N3O5S

• Molecular Weight :

  349.36

• References & Citations :

  [1]Fanwang Meng, et al. Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. J Med Chem. 2015 Oct 22;58 (20) :8166-81.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  DOT1L; EHMT2/G9a/KMT1C

• CAS Number :

  [303141-21-1]